Reduction in urinary angiotensinogen levels and improvement of proteinuria by renin–angiotensin system blockade in pediatric chronic kidney disease patients with very low birth weight

The developmental origins of health and chronic kidney disease: Current status and practices in Japan

“…The increase in uAGT reflected de novo production of AGT within the kidney and that uAGT can be used as a marker for the activation of the intrarenal RAS. Kidney‐specific RAS is a sensitive marker of renal glomerular damage, and there is already a report of the same 50 . The RAS is important for blood pressure and circulatory blood flow regulation as well as kidney development and growth.…”

“…Yamamura‐Miyazaki et al . reported that treatment with a RAS inhibitor is beneficial for suppressing intrarenal RAS activation and CKD progression in children with VLBW 50 . In their study, nine Japanese children with CKD (stages 1–2) who had been born with VLBW were started on RAS blockade with candesartan.…”

“…Kidney-specific RAS is a sensitive marker of renal glomerular damage, and there is already a report of the same. 50 The RAS is important for blood pressure and circulatory blood flow regulation as well as kidney development and growth. Angiotensinogen, a substrate of the RAS, is an excellent biomarker of renal activation and an indicator of renal development in infants.…”

“…Yamamura-Miyazaki et al reported that treatment with a RAS inhibitor is beneficial for suppressing intrarenal RAS activation and CKD progression in children with VLBW. 50 In their study, nine Japanese children with CKD (stages 1-2) who had been born with VLBW were started on RAS blockade with candesartan. The uAGT-to-uCr ratio decreased from 61.9 AE 44.7 to 16.8 AE 14.4 lg/g (P = 0.015) after treatment with candesartan for 47.6 AE 25.0 months.…”